NCT06022224View on ClinicalTrials.gov

A 2nd Generation E1/E2B/E3-Deleted Adenoviral COVID-19 Vaccine: The TCELL VACCINE TRIAL

PHASE2/PHASE3TerminatedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

December 9, 2020

Primary Completion Date

June 23, 2022

Study Completion Date

July 19, 2023

Conditions
COVID-19
Interventions
BIOLOGICAL

hAd5-S-Fusion+N-ETSD

Clear and colorless liquid. Each vaccine is supplied in a 2-mL vial containing 1.0 mL of extractable vaccine at a concentration of 1 × 10\^11 viral particles/mL.

BIOLOGICAL

Placebo (0.9% (w/v) saline)

Clear and colorless liquid.

Trial Locations (1)

92663

Hoag Memorial Hospital Presbyterian, Newport Beach

Sponsors

Lead Sponsor

ImmunityBio, Inc.
All Listed Sponsors
lead

ImmunityBio, Inc.

INDUSTRY

NCT06022224 - A 2nd Generation E1/E2B/E3-Deleted Adenoviral COVID-19 Vaccine: The TCELL VACCINE TRIAL | Biotech Hunter | Biotech Hunter